Video

Vitiligo Prevalence and Patient Burden

Author(s):

Seemal R. Desai, MD,Pearl E. Grimes, MD

John E. Harris, MD, PhD, reviews factors that shape prevalence of vitiligo and also explores the impact of vitiligo on patient quality of life.

Related Videos
Oral Upadacitinib Significantly Reduces Facial, Total Nonsegmental Vitiligo Through 52 Weeks
Amit Pandya, MD: The Discovery of Oral Tranexamic Acid for Melasma
Amit Pandya, MD: Ruxolitinib Cream in Real-World Vitiligo Patients of Color
Related Content
T-VASI, F-VASI are Reliable Tools to Measure Nonsegmental Vitiligo Progress
October 31st 2024

T-VASI, F-VASI are Reliable Tools to Measure Nonsegmental Vitiligo Progress

Chelsie Derman
The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes
May 10th 2023

The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

HCP Live Staff
Cendakimab Effective Among Individuals with Moderate to Severe Eczema
July 23rd 2024

Ruxolitinib Cream Led to Meaningful Repigmentation Across Different Body Regions

Tim Smith
What Ruxolitinib Cream Meant For Dermatology in 2022
December 20th 2022

What Ruxolitinib Cream Meant For Dermatology in 2022

Kevin Kunzmann
Vitiligo Patients Face Higher All-Cause, Vitiligo-Related Costs Compared to Those Without
February 1st 2024

Vitiligo Patients Face Higher All-Cause, Vitiligo-Related Costs Compared to Those Without

Tim Smith
Wendy Bollag, PhD | Credit: Augusta University
January 30th 2024

Patients With Vitiligo, End-Stage Renal Disease Face Greater Risk of Infection

Abigail Brooks, MA
© 2024 MJH Life Sciences

All rights reserved.